Paul Hastings Chair of the Litigation practice in New York Preston K. Ratliff II has been named among Minority Corporate Counsel Association’s (MCCA) 2024 Rainmakers. Mr. Ratliff is noted for his work on complex, high-stakes litigation with an emphasis on patent litigation in the biotechnology, pharmaceutical, chemical, agricultural, and renewable fuel sectors. Mr. Ratliff’s notable work includes being lead counsel in a hotly-contested, multi-billion dollar breach of contract intellectual property biotechnology dispute involving antibody-drug conjugates for the treatment of various cancers, lead counsel that locked in full patent protection and revenues arising from Sumitomo Dainippon Pharma’s chemical compound patent for its billion-dollar-plus-per-year schizophrenia and bipolar drug, Latuda®, and co-led a trial team that won an important trial victory for Merck concerning its pharmaceutical product Emend® for Injection, which is used in the prevention of nausea and vomiting associated with cancer chemotherapy.

MCCA’s annual Rainmakers list honors 16 exceptional attorneys from across the nation who have achieved remarkable success through their innovative, consistent business development strategies and client development skills.

Paul Hastings’ Intellectual Property practice advises clients on important, complex IP matters, providing innovative solutions for our clients’ challenges with a track record of success in patent and trade secret litigation and other IP disputes in trial and appeals courts, at the PTAB and the ITC, and in arbitral tribunals.